WO2013184986A3 - Methods and compositions for inhibiting angiogenesis - Google Patents

Methods and compositions for inhibiting angiogenesis Download PDF

Info

Publication number
WO2013184986A3
WO2013184986A3 PCT/US2013/044637 US2013044637W WO2013184986A3 WO 2013184986 A3 WO2013184986 A3 WO 2013184986A3 US 2013044637 W US2013044637 W US 2013044637W WO 2013184986 A3 WO2013184986 A3 WO 2013184986A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
compositions
seq
amino acid
present
Prior art date
Application number
PCT/US2013/044637
Other languages
French (fr)
Other versions
WO2013184986A2 (en
Inventor
Olga Volpert
Yelena Mirochnik
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,357 external-priority patent/US9096689B2/en
Application filed by Northwestern University filed Critical Northwestern University
Publication of WO2013184986A2 publication Critical patent/WO2013184986A2/en
Publication of WO2013184986A3 publication Critical patent/WO2013184986A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease. In some embodiments, the present invention provides compositions comprising an isolated peptide, wherein the peptide consists of an amino acid sequence selected from: SEQ ID NOs:2, 12, 13, 22, 23, 33, 34, 41, 42, 43-49, 52, 53, 62, 63, 73, 74, 84, 85, and 92-118. In other embodiments, the peptide comprises, or consists of, SEQ ID NOs: 1-49 and 52-118. In certain embodiments, the peptide comprises, or consists of, or consists essentially of SEQ ID NO:102 (NFGYDLYRVRS). In certain embodiments, one or more of the amino acid in any of these sequences are substituted with modified versions of the appropriate amino acid or amino acids that do not detrimentally affect the anti-angiogenic activity of the peptide.
PCT/US2013/044637 2012-06-08 2013-06-07 Methods and compositions for inhibiting angiogenesis WO2013184986A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/492,357 2012-06-08
US13/492,357 US9096689B2 (en) 2007-11-07 2012-06-08 Methods and compositions for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
WO2013184986A2 WO2013184986A2 (en) 2013-12-12
WO2013184986A3 true WO2013184986A3 (en) 2014-01-30

Family

ID=49712860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/044637 WO2013184986A2 (en) 2012-06-08 2013-06-07 Methods and compositions for inhibiting angiogenesis

Country Status (1)

Country Link
WO (1) WO2013184986A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081668B2 (en) 2016-04-26 2018-09-25 Northwestern University Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
KR101998155B1 (en) * 2017-09-22 2019-07-10 (주)케어젠 Peptides for inhibiting angiogenesis and the use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189519A1 (en) * 2002-09-26 2006-08-24 Karl Volz Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
US20080274967A1 (en) * 2005-11-14 2008-11-06 Galia Maik-Rachline Variants of Pigment Epithelium Derived Factor and Uses Thereof
US20100331263A1 (en) * 2007-11-07 2010-12-30 Northwestern University Methods and compositions for inhibiting angiogenesis
US20120316115A1 (en) * 2007-11-07 2012-12-13 Northwestern University Methods and compositions for inhibiting angiogenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189519A1 (en) * 2002-09-26 2006-08-24 Karl Volz Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
US20080274967A1 (en) * 2005-11-14 2008-11-06 Galia Maik-Rachline Variants of Pigment Epithelium Derived Factor and Uses Thereof
US20100331263A1 (en) * 2007-11-07 2010-12-30 Northwestern University Methods and compositions for inhibiting angiogenesis
US20120316115A1 (en) * 2007-11-07 2012-12-13 Northwestern University Methods and compositions for inhibiting angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAWSON ET AL.: "Pigment Epithelium Derived Factor: A Potent Inhibitor of Angiogenesis", SCIENCE, vol. 285, no. 5425, 9 July 1999 (1999-07-09), pages 245 - 248 *
MIROCHNIK ET AL.: "Short Pigment Epithelial-Derived Factor-Derived Peptide Inhibits Angiogenesis and Tumor Growth", CLINICAL CANCER RESEARCH, vol. 15, no. 5, 17 February 2009 (2009-02-17), pages 1655 - 1663 *

Also Published As

Publication number Publication date
WO2013184986A2 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
EP4223772A3 (en) Optimized factor viii gene
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2014202616A3 (en) Rasamsonia gene and use thereof
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
WO2014202622A3 (en) Rasamsonia gene and use thereof
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
EP2470670A4 (en) Coagulation factor vii compositions and methods of making and using same
WO2013164479A3 (en) Improved chymosine enzyme variants
MX2015003310A (en) Novel il-17a binding molecules and medical uses thereof.
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
IN2015DN03206A (en)
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
WO2012017329A3 (en) Method for targeted genomic events in algae
EA201691011A1 (en) SEQUENCE OF MODIFIED ENDOLYSINE EL188
MX2016006277A (en) Modified kz144 endolysin sequence.
EP4043558A3 (en) Kaurenoic acid hydroxylases
MX2015001542A (en) Method.
WO2016036635A8 (en) Chromobacterium subtsugae genes
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
WO2013184986A3 (en) Methods and compositions for inhibiting angiogenesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13801004

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13801004

Country of ref document: EP

Kind code of ref document: A2